BUZZ-Ocular Therapeutix rises on plans to fast-track FDA filing for eye disease drug

Reuters12-08
BUZZ-<a href="https://laohu8.com/S/OCUL">Ocular Therapeutix</a> rises on plans to fast-track FDA filing for eye disease drug

** Shares of Ocular Therapeutix OCUL.O rise 13.5% to $14.28 in premarket trading

** OCUL says its plans to submit a marketing application for its experimental eye disease drug, Axpaxli, to treat wet age-related macular degeneration after one-year data from its ongoing late-stage trial, expected in the first quarter of 2026

** Wet AMD is a leading cause of vision loss in older adults, marked by abnormal blood vessel growth in the retina

** Company says the study is designed to show superiority over Regeneron Pharma's REGN.O Eylea and aligns with recent FDA guidance that a single, well-controlled trial may support approval

** As of last close, stock up 47.3% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment